| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
2 companies
Enavate Sciences Gp, LLC last filed a Form 4 in October 2024, as 10% Owner at CAMP. The filings on record cover 2 companies.
At the last filing, the largest reported position was 3,761,359 shares of ZBIO. Net of sales, the ZBIO filings show accumulation of 882,353 shares.
Enavate Sciences Gp, LLC has 2 Form 4 filings on record from September 2024 to October 2024, across 2 companies: 10% Owner at Camp4 Therapeutics (CAMP), 2024; 10% Owner at Zenas BioPharma (ZBIO), 2024.
The 4 reported transactions were 2 conversions and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $30.0M and no sales.
The largest open-market purchase was 882,353 shares of ZBIO at an average $17.00 on September 16, 2024, about $15.0M. Twelve months later ZBIO was up 2%.
Shares as reported in the last Form 4 for each company; the most recent is from October 2024. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.